

# EXHIBIT A

**UNITED STATES DISTRICT COURT  
EASTERN DISTRICT OF LOUISIANA**

**JEFFERSON RADIATION ONCOLOGY, L.L.C.**  
**V.**  
**ADVANCED CARE SCRIPTS, INC.**

**CIVIL ACTION NO.:**  
**SECTION:**

**CLASS ACTION COMPLAINT**

Plaintiff, Jefferson Radiation Oncology, L.L.C. (hereinafter referred to as “Plaintiff”), brings this action on behalf of itself and all others similarly situated, and avers:

**Introduction**

1. More than two decades ago, the Telephone Consumer Protection Act of 1991, 47 U.S.C. § 227 (hereinafter referred to as “TCPA”) was enacted into law. The law responded to countless complaints by American consumers and businesses about the cost, disruption and nuisance imposed by junk faxes. The law prohibited the transmission of facsimile advertising without prior express invitation or permission of the recipient. In 2005, because consumers and businesses continued to be besieged with junk faxes, Congress strengthened the law by amending it through the Junk Fax Prevention Act of 2005 (hereinafter referred to as “JFPA”). As amended, the law requires senders to include in their faxed advertisements a clear and conspicuous notice that discloses to recipients their right to stop future junk faxes and explains how to exercise that right.
2. Plaintiff brings this class action to recover damages for and enjoin massive junk faxing by defendant, Advanced Care Scripts, Inc. (hereinafter referred to as “Defendant”) in direct violation of the TCPA. Upon information and belief, Plaintiff avers that Defendant has blasted thousands of junk faxes nationwide in direct violation of the TCPA and the

regulations promulgated under the act by the Federal Communications Commission (hereinafter referred to as “FCC”). Defendant’s violation include, but are not limited to, the facsimile transmission of an unsolicited advertisement on February 17, 2015, March 24, 2015, and April 10, 2015 to Plaintiff’s facsimile telephone machine, a true and correct copy of which is attached as hereto as Exhibit 1, Exhibit 2, and Exhibit 3.

### **Standing and Jurisdiction**

3. This Court has subject matter jurisdiction over this matter and Plaintiff has standing to seek relief in this Court because 47 U.S.C. § 227(b)(3) authorizes commencement of an action in an appropriate state court to obtain damages in the amount of \$500 for each violation of the TCPA, to enjoin further violations of the Act, or for both such actions.

### **The Parties**

4. *Individual Plaintiff/Class Representative.* Plaintiff, Jefferson Radiation Oncology, L.L.C., is, and at all times relevant hereto was, a limited liability company duly organized and existing under the laws of the state of Louisiana, with its principal place of business in Metairie, Louisiana. Plaintiff is, and at all times relevant hereto was, the subscriber of the facsimile telephone number (504) 455-4857, to which the fax attached hereto as Exhibit 1, Exhibit 2, and Exhibit 3 were sent.
5. *Defendant:* Upon information and belief, defendant, Advanced Care Scripts, Inc., is, and at all times relevant hereto was, a corporation organized and existing under the laws of the state of Florida, having its principal place of business in Cincinnati, Ohio.

### **The JFPA’s Prohibition Against Junk Faxing**

6. By the early 1990s, advertisers had exploited facsimile telephone technology to blanket the country with junk fax advertisements. This practice imposed tremendous disruption, annoyance, and cost on the recipients. Among other things, junk faxes tie up recipients’

telephone lines and facsimile machines, misappropriate and convert recipients' fax paper and toner, require recipients to sort through faxes to separate legitimate fax communications from junk advertisements and to discard the latter. Congress responded to the problem by passing the TCPA. The TCPA made it unlawful for any person "to use any telephone facsimile machine, computer, or other device to send, a telephone facsimile machine, an unsolicited advertisement." 47 U.S.C. §227(b)(1)(C). The anti-junk fax law was enacted to eradicate "the explosive growth in unsolicited facsimile advertising, or junk fax." H.R. Rep. No. 102-317 (1991).

7. In the decade following the law's enactment, however, American consumers and businesses continued to be "besieged" by junk faxes because senders refused to honor requests by recipients to stop. FCC, Report and Order on Reconsideration of Rules and Regulations Implementing the TCPA of 1991, 29 Comm. Reg. 830 ¶ 186 (2003). Congress responded by strengthening the law through the JFPA of 2005. The JFPA continues the prohibition against sending unsolicited advertisements via facsimile transmission. The FCC has defined a "sender" to include any "person or entity on whose behalf a facsimile unsolicited advertisement is sent or whose goods or services are advertised or promoted in the unsolicited advertisement." 47 C.F.R. § 64.1200(a)(3), (f)(8). The TCPA defines "unsolicited advertisement" as "any material advertising the commercial availability or quality of any property, goods, or services which is transmitted to any person without that person's prior express invitation or permission, in writing or otherwise." 47 U.S.C. §227(a)(5).
8. The JFPA for the first time required senders to disclose to recipients their right and ability to stop future junk faxes (hereinafter collectively the "Opt-Out Notice Requirements"). 47 U.S.C. §227(b)(1)(C)(iii), (b)(2)(D), (b)(2)(E), (d)(2); 47 CFR § 64.1200(a)(4)(iii)-(vii).

Advertisers must place the notice clearly and conspicuously on the first page of the fax transmission and provide prescribed disclosures that Congress believed essential to enable junk fax recipients to opt-out of future faxes. Compliance with the Opt-Out Notice Requirements is neither difficult nor costly. But these requirements are important consumer protections bestowed by Congress upon American consumers and businesses by giving them the right to stop unwanted junk faxes and to require senders to disclose the right and explain how to exercise that right. Even a fax advertisement sent with permission of the recipient is unlawful if the sender fails to comply with the Opt-Out Notice Requirements. 47 C.F.R. § 64.1200(a)(4)(iii)-(vii).

**The Advanced Care Scripts, Inc.’s Junk Fax Campaign**

9. Defendant, Advanced Care Scripts, Inc., engages in the management and dispensing of specialty medications and oral oncology products, as well as provides Medicare reimbursement support services.
10. Upon information and belief, Plaintiff alleges that to advertise their goods and/or services, Defendant has blasted thousands of junk faxes to businesses. Plaintiff alleges Defendant obtained from third parties lists of facsimile telephone numbers and uses such lists to send its junk faxes. Plaintiff alleges that Defendant has blasted junk faxes without first obtaining recipients’ prior express permission to receive facsimile advertising, and without complying with the Opt-Out Notice Requirements, in direct violation of the TCPA, JFPA and the FCC’s regulations promulgated thereunder.
11. The junk faxes sent to Plaintiff were part of Defendant’s junk fax marketing campaign. Exhibit 1 promotes the availability of the drugs Nexavar and Stivarga, while advertising products and services Plaintiff and its patients can “take full advantage of”, including access to oral and injectable therapies, blister packing for oral medications, patient

counseling, and complete insurance investigation to determine the best financial option. The fax also provides a referral form to be used by Plaintiff, as well as a telephone number to call should Plaintiff want to speak to a Defendant representative about its products and services. Exhibit 2 provides identical information as to Exhibit 1, but pertains to the drug Farydak. Exhibit 3 provides identical information as to Exhibit 1, but pertains to the drug Jadenu. Plaintiff did not give Defendant prior express permission to send these or any other fax advertisements to it.

### **Class Action Allegations**

12. *Statutory Reference.* This action is properly maintainable as a class action under authority of Federal Rule Civil Procedure 23 because: (a) the class is so numerous that joinder of all members is impracticable; (b) there are questions of fact or law common to the class, which common questions predominate over questions affecting only individual members; (c) the representative parties will fairly and adequately protect the interest of the class; and (d) the class action is an appropriate method for the fair and efficient adjudication of the controversy.
13. *Class Definition.* The Plaintiff Class (hereinafter referred to as “Plaintiff Class”) consists of all persons and entities that are subscribers of telephone numbers to which within four years of the filing of this Complaint, Defendant sent facsimile transmissions with content that discusses, describes, promotes products and/or services offered by Defendant, and does not contain the notice required by 47 U.S.C. § 227(b)(1)(C)(iii), (b)(2)(D), (b)(2)(E), (d)(2) or 47 C.F.R. § 64.1200(a)(4)(iii)-(vii).
14. *Class Size.* Upon information and belief, Plaintiff avers that the Plaintiff Class numbers are in the thousands of persons or entities.

15. *Adequacy of Representation.* The Plaintiff Class will be well represented by the class representative and class counsel. Plaintiff appreciates the responsibility of a class representative and understands the nature and significance of the claims made in this case. Plaintiff can fairly and adequately represent and protect the interests of the Plaintiff Class because there is no conflict between its interests and the interests of other class members. Proposed class counsel has the necessary resources, experience and ability to prosecute this case on a class action basis.
16. *Impracticability of Joinder.* Joinder of all Plaintiff Class members is impracticable due to the class' size and due to the relatively small potential monetary recovery for each Plaintiff Class member, in comparison to the time and costs associated with joinder in the litigation on an individual basis.
17. *Common Questions of Law and Fact are Predominant.* Questions of law and fact common to the class predominate over questions affecting only individual class members. Numerous questions may be jointly tried and would not require each member individually to litigate numerous and substantial questions to determine his or her right of recover following the class judgment.
18. *Common Questions of Fact.* This case presents numerous questions of fact that are common to all class members' claims. Defendant has engaged in a standardized course of conduct vis-à-vis class members, and Plaintiff's injuries arise out of that conduct. Plaintiff is informed and believes and upon such information and belief avers that the case arises out of a common nucleus of fact because, among other things, all junk faxes advertised Defendant's goods and services; all junk faxes were prepared, developed and sent by Defendant in the same manner for all recipients; and the faxes are the product of an

organized fax-blasting campaign targeted to the class.

19. *Common Questions of Law.* The case presents numerous common questions of law, including, but not limited to:

- (1) Whether the faxes at issue advertise the commercial availability or quality of property, goods or services and therefore fall within the ambit of the TCPA, JFPA and the FCC's regulations promulgated thereunder;
- (2) Defendant's mode and method of obtaining the telephone numbers to which the junk faxes were sent and whether the mode and method complied with the requirements of subsection 47 U.S.C. §227 (b)(1)(C)(ii) and the FCC's regulations promulgated thereunder;
- (3) Whether Defendant complied with the Opt-Out Notice Requirements of the TCPA, JFPA and the FCC's regulations promulgated thereunder, and the legal consequences of the failure to comply with those requirements;
- (4) What constitutes a knowing or willful violation of the TCPA within the meaning of section (b)(3);
- (5) Whether Defendant committed knowing or willful violations of the TCPA;
- (6) Whether damages should be increased on account of Defendant's knowing or willful violations of the TCPA and, if so, by what amount; and
- (7) Whether injunctive relief is warranted to enjoin Defendant from further violations of the TCPA and JFPA.

20. *Appropriate Method for Fair and Efficient Resolution of the Controversy.* A class action is an appropriate method for the fair and efficient adjudication of the controversy for several reasons:

- (1) Prosecuting separate actions by individual class members would create a risk inconsistent or varying adjudications that would establish incompatible standards of conduct for Defendant;
- (2) Because Defendant has acted on grounds that apply generally to the class, final injunctive relief is appropriate respecting the class as a whole;
- (3) Questions of law and fact common to members of the class predominate over any questions affecting only individual members, and a class action is superior to other available methods for the fair and efficient adjudication of the controversy;
- (4) Absent class certification, there is a possibility of multiple individual cases and, therefore, class adjudication will conserve judicial resources and will avoid the possibility of inconsistent rulings.
- (5) Most members of the Plaintiff Class are not likely to join or bring an individual action due to, among other reasons, the small amount to be recovered relative to the time, effort and expense necessary to join or bring an individual action. Because the statutory minimum damage is \$500 per violation and the TCPA and JFPA does not authorize an award of attorneys' fees to a successful plaintiff, individual action to remedy Defendant's violations of the TCPA would be grossly uneconomical. As a practical matter, the claims of the vast majority of the Plaintiff Class are not likely to be redressed absent class certification.
- (6) Equity dictates that all persons who stand to benefit from the relief sought herein should be subject to the lawsuit and, hence, subject to an order spreading the cost of litigation among class members in relationship to the benefits received.

**Cause of Action for Violation of 47 U.S.C. § 227**

21. *Defendant's Violation of the Act.* Within four years of the filing of this Complaint and including, without limitation, February 17, 2015, March 24, 2015, and April 10, 2015, Defendant violated the TCPA, JFPA and the FCC's regulations promulgated under the TCPA by sending unsolicited advertisements via facsimile from telephone facsimile machines, computers, or other devices to telephone facsimile machines of Plaintiff and members of the Plaintiff Class. Among other things, Defendant violated the TCPA, JFPA and the FCC's regulations because they (a) transmitted the advertisements without receiving recipients' prior express invitation or permission; and (b) failed to comply with the Opt-Out-Notice Requirements by failing to make the disclosures required by 47 U.S.C. § 227(b)(1)(C)(iii), (b)(2)(D) and (b)(2)(E), and by 47 C.F.R. § 64.1200(a)(4)(iii)-(vii).
22. Defendant is a sender of the junk faxes alleged in this Complaint because it is the person or entity on whose behalf the facsimile unsolicited advertisements were sent and its property, goods and services are advertised or promoted in the unsolicited advertisement.
23. *Right of Private Action.* Under section (b)(3) of the TCPA, Plaintiff has a private right of action to bring this action on behalf of itself and on behalf of the Plaintiff Class to redress Defendant's violations of the TCPA.
24. *Injunctive Relief.* Subsection (b)(3)(A) of the TCPA authorizes Plaintiff to bring an action to enjoin a violation of the TCPA. Plaintiff requests that preliminary and permanent injunctions issue to:
  - (1) Prohibit Defendant, their employees, agents, representatives, contractors, affiliates and all persons and entities acting in concert with Defendant, from committing further violations of the TCPA, and thereby prohibiting Defendant, their employees, agents, representatives, contractors, affiliates, and all persons and entities acting with

Defendant, from sending any further unsolicited faxed advertisements to any person or entity;

- (2) Require Defendant to deliver to Plaintiff all records of facsimile advertisements since four years of the filing of this Complaint, including all content sent via facsimile, transmission lists, and fax confirmation lists;
- (3) Require Defendant to adopt ongoing educational, training and monitoring programs to ensure compliance with the TCPA and JFPA, and limiting facsimile advertising activity to personnel who have undergone such training;
- (4) Require Defendant to provide written notice to all persons and entities to whom Defendant sent via facsimile transmission unsolicited advertisements, warning such persons and entities that the facsimile transmission of unsolicited advertisements is in violation of the TCPA and JFPA and that they should not be led or encouraged in any way by Defendant's facsimile transmissions to fax unsolicited advertisements of their own; and
- (5) Require Defendant to conspicuously place on the homepage of their respective websites the warnings contained in (4) of this Paragraph 24.

25. *Damages.* Subsection (b)(3)(B) of the TCPA provides for the recovery of damages in the minimum amount of \$500 for each violation of the TCPA by Defendant. In addition, Plaintiff is informed and believes and upon such information and belief avers that Defendant committed its violations willfully or knowingly and that the amount of statutory damages should be trebled, as also authorized by subsection (b)(3) of the TCPA.

#### **Prayer for Relief**

WHEREFORE, Plaintiff and the Plaintiff Class pray for judgment against Defendant:

- (1) Certifying a class consisting of all persons and entities that are subscribers of telephone numbers to which within four years of the filing of this Complaint, Defendant sent facsimile transmissions with content that discusses, describes, or promotes products and/or services offered by Defendant, and does not contain the notice required by 47 U.S.C. § 227(b)(1)(C)(iii), (b)(2)(D) and (b)(2)(E), and by 47 C.F.R. § 64.1200(a)(4)(iii)-(vii).
- (2) Appointing Plaintiff as representative for the Plaintiff Class and awarding Plaintiff an incentive award for its efforts as class representative;
- (3) Appointing Plaintiff's counsel as counsel for the Plaintiff Class;
- (4) In accordance with subsection (b)(3)(B) of the TCPA and JFPA, for an award of statutory damages in the amount of \$500 for each violation of the Act and the trebling of such statutory damages, exclusive of interest costs, according to proof;
- (5) For injunctive relief in accordance with subsection (b)(3)(A) of the TCPA and JFPA, (1) prohibiting Defendant, their employees, agents, representatives, contractors, affiliates and all persons and entities acting in concert with Defendant, from committing further violations of the TCPA, and thereby prohibiting Defendant, their employees, agents, representatives, contractors, affiliates, and all persons and entities acting in concert with Defendant, from sending any further unsolicited faxed advertisements to any person or entity; (2) requiring Defendant to deliver to Plaintiff all records of facsimile advertisements since four years of the filing of this Complaint, including all content sent via facsimile, transmission lists, and fax confirmation lists; (3) requiring Defendant to adopt ongoing educational, training and monitoring activity to personnel who have undergone such training; (4) requiring Defendant to provide written notice to all persons and

entities to whom Defendant sent via facsimile transmission unsolicited advertisements, informing such persons and entities that Defendant's facsimile transmission of unsolicited advertisements mislead recipients to fax unsolicited advertisements of their own; and (5) requiring Defendant to conspicuously place on the homepage of their respective websites the warnings contained in (4) of this subparagraph 5;

- (6) Ordering payment of Plaintiff's costs of litigation, including without limitation costs of suit and attorneys' fees, spread among the members of the Plaintiff Class in relation to the benefits received by the Plaintiff Class;
- (7) For pre-judgment interest;
- (8) For costs of suit herein from Defendant;
- (9) For such other and further relief as the Court shall deem just and proper.

Respectfully Submitted:

*/s/ George B. Recile*

---

GEORGE B. RECILE (#11414)  
PRESTON L. HAYES (#29898)  
RYAN P. MONSOUR (#33286)  
MATTHEW A. SHERMAN (#32687)  
PATRICK R. FOLLETTE (#34547)  
*Chehardy, Sherman, Ellis, Murray, Recile,  
Griffith, Stakelum & Hayes, L.L.P.*  
One Galleria Boulevard, Suite 1100  
Metairie, Louisiana 70001  
Telephone: (504) 833-5600  
Facsimile: (504) 613-4528  
*Counsel for Plaintiff*



**ACS** *Advanced Care Scripts*  
Omnicare Specialty Care Group


ACS has been selected as part of Bayer's limited network to dispense NEXAVAR<sup>®</sup> (sorafenib) and STIVARGA<sup>®</sup> (regorafenib)

Available TODAY through ACS!

**By referring your patients to ACS, you and your patients can take full advantage of...**

- ⊗ Access to *Injectable* and *Oral Therapies* including but not limited to Afinitor<sup>®</sup>, Ibrance<sup>®</sup>, Revlimid<sup>®</sup>, Temodar<sup>®</sup>, Xeloda<sup>®</sup>, Xtandi<sup>®</sup> & Zytiga<sup>®</sup>
- ⊗ Blister Packing for Oral Medications to Promote Compliance
- ⊗ Patient counseling from trained nurses and pharmacists
- ⊗ Complete Insurance investigation including
  - ✓ Prior authorization initiation
  - ✓ Appeals assistance
  - ✓ Copayment assistance to determine best financial option for patient.

**Referring your patients is as easy as 1, 2, 3!**



Questions? Please Call your ACS Representative 877-985-6337

To be removed from future faxes call 877-573-7105



**ACS** Advanced Care Scripts  
Oncology Specialty Care Group

# Oral Oncology Referral Form

Phone: 877-985-MEDS(6337) Fax: 866-679-7131

**Patient Information OR Attach Face Sheet**

First Name:	Middle Initial:	Last Name:	
Date of Birth:	Gender: <input type="checkbox"/> M <input type="checkbox"/> F	SSN:	
Street Address:	City:	State:	Zip Code:
Home Phone:	Work Phone:	Cell Phone:	

**Insurance Information OR Attach Insurance Information**

Rx Card Insurance Name:	ID#:	BIN:	PCN:	Phone #:
Primary Insurance Name:	ID#:	GROUP#:		Phone #:
Secondary Insurance Name:	ID#:	GROUP:	Phone #:	

**Prescription Information**

<b>POMALYST</b> Dosing: 1mg   2mg   3mg   4mg (circle one) Directions: _____ Qty: _____   Rest Period: _____ Auth number: _____ Date: _____ Confirmation: _____ Date: _____	<b>REVLIMID</b> Dosing: 2.5mg   5mg   10mg   15mg   20mg   25mg (circle one) Directions: _____ Qty: _____   Rest Period: _____ Auth number: _____ Date: _____ Confirmation: _____ Date: _____	<b>THALOMID</b> Dosing: 50mg   100mg   150mg   200mg (circle one) Directions: _____ Qty: _____   Rest Period: _____ Auth number: _____ Date: _____ Confirmation: _____ Date: _____	<b>Risk Category</b> <input type="checkbox"/> Adult Female, NOT of Reproductive Potential <input type="checkbox"/> Adult Female, Reproductive Potential <input type="checkbox"/> Adult Male <input type="checkbox"/> Male Child <input type="checkbox"/> Female Child, NOT of Reproductive Potential <input type="checkbox"/> Female Child, Reproductive Potential
--	--	---	--

**Drug List**

<input type="checkbox"/> Afinitor <input type="checkbox"/> Bosulif <input type="checkbox"/> Emend <input type="checkbox"/> Erivedge <input type="checkbox"/> Gleevec <input type="checkbox"/> Ibrance <input type="checkbox"/> Inlyta <input type="checkbox"/> Intron A <input type="checkbox"/> Mekinist <input type="checkbox"/> Nexavar <input type="checkbox"/> Promacta <input type="checkbox"/> Sprycel <input type="checkbox"/> Stivarga <input type="checkbox"/> Sutent	<input type="checkbox"/> Sylatron <input type="checkbox"/> Tafenlar <input type="checkbox"/> Tarceva <input type="checkbox"/> Tasigna <input type="checkbox"/> Temodar <input type="checkbox"/> Tykerb <input type="checkbox"/> Votrient <input type="checkbox"/> Xalkori <input type="checkbox"/> Xeloda <input type="checkbox"/> Xtandi <input type="checkbox"/> Zolboraf <input type="checkbox"/> Zykadia <input type="checkbox"/> Zytiga <input type="checkbox"/> Other	<b>STRENGTH:</b>  <b>SIG/DIRECTIONS/CYCLE:</b>  <b>REFILLS:</b>	<b>QUANTITY:</b>
--	--	---	------------------

Secondary Prescription- Drug Name: \_\_\_\_\_ Dose: \_\_\_\_\_

Sig/Directions/Cycle: \_\_\_\_\_ Quantity: \_\_\_\_\_ Refills: \_\_\_\_\_

**Clinical Information**

Primary Diagnosis:	ICD-9:	Weight:	Pounds	Height:	Inches
Secondary Diagnosis:	ICD-9:				

Allergies: \_\_\_\_\_ Failed Therapies: \_\_\_\_\_

Patient Medication List (or attach separately): \_\_\_\_\_

**Prescriber Information**

Prescriber First Name:	Prescriber Last Name:	Facility Name:
DEA:	State License #:	NPI: UPIN: Office Contact E-mail:
Office Address:	City:	State: Zip Code:
Office Phone:	Office Fax:	Office Contact Name:

**SIGNATURE OF LICENSED PRESCRIBER IS REQUIRED TO VALIDATE PRESCRIPTIONS**

I authorize Advanced Care Scripts to initiate a Prior Authorization on my behalf.

Prescriber Signature: \_\_\_\_\_  
 Prescriber must write "Brand Medically Necessary" in own handwriting to prevent substitution



**ACS** *Advanced Care Scripts*  
Omnicare Specialty Care Group


# Farydak<sup>®</sup> (Panobinostat) is now available through ACS Specialty Pharmacy.

Farydak<sup>®</sup> is FDA-approved for the treatment of relapsed and refractory multiple myeloma.

**By referring your patients to ACS, you and your patients can take full advantage of...**

- Access to oral and injectable therapies and including but not limited to Revlimid<sup>®</sup>, Pomalyst<sup>®</sup>, Tarceva<sup>®</sup>, Ibrance<sup>®</sup>, Sutent<sup>®</sup>, Nexavar<sup>®</sup>, Stivarga<sup>®</sup>, Gleevec<sup>®</sup>
- Blister packing for oral medications to improve medication adherence and compliance
- Patient counseling from expertly trained nurses and pharmacists
- Complete insurance investigation to determine the best financial option
  - ✓ Prior authorization initiation
  - ✓ Appeals assistance
  - ✓ Copayment assistance for patient

**Refer your patients in 3 easy steps!**



Questions? Please call your ACS Representative at 877-985-6337  
To be removed from future faxes call 877-573-7105



**ACS** Advanced Care Scripts  
Omnicare Specialty Care Group

# Oral Oncology Referral Form

Phone: 877-985-MEDS(6337) Fax: 866-679-7131

**Patient Information OR Attach Face Sheet**

First Name:	Middle Initial:	Last Name:	
Date of Birth:	Gender: <input type="checkbox"/> M <input type="checkbox"/> F	SSN:	
Street Address:	City:	State:	Zip Code:
Home Phone:	Work Phone:	Cell Phone:	

**Insurance Information OR Attach Insurance Information**

Rx Card Insurance Name:	ID#:	BIN:	PCN:	Phone #:
Primary Insurance Name:	ID#:	GROUP#:		Phone #:
Secondary Insurance Name:	ID#:	GROUP:	Phone #:	

**Prescription Information**

POMALYST	REVLIMID	THALOMID	Risk Category
Dosing: 1mg   2mg   3mg   4mg (circle one) Directions: _____ Qty: _____   Rest Period: _____ Auth number: _____ Date: _____ Confirmation: _____ Date: _____	Dosing: 2,5mg   5mg   10mg   15mg   20mg   25mg (circle one) Directions: _____ Qty: _____   Rest Period: _____ Auth number: _____ Date: _____ Confirmation: _____ Date: _____	Dosing: 50mg   100mg   150mg   200mg (circle one) Directions: _____ Qty: _____   Rest Period: _____ Auth number: _____ Date: _____ Confirmation: _____ Date: _____	<input type="checkbox"/> Adult Female, NOT of Reproductive Potential <input type="checkbox"/> Adult Female, Reproductive Potential <input type="checkbox"/> Adult Male <input type="checkbox"/> Male Child <input type="checkbox"/> Female Child, NOT of Reproductive Potential <input type="checkbox"/> Female Child, Reproductive Potential

**Drug List**

<input type="checkbox"/> Affinitor <input type="checkbox"/> Bosulif <input type="checkbox"/> Emend <input type="checkbox"/> Erivedge <input type="checkbox"/> Farydak <input type="checkbox"/> Gleevec <input type="checkbox"/> Ibrance <input type="checkbox"/> Inlyta <input type="checkbox"/> Intron A <input type="checkbox"/> Mekinist <input type="checkbox"/> Nexavar <input type="checkbox"/> Promacta <input type="checkbox"/> Sprycel <input type="checkbox"/> Stivarga <input type="checkbox"/> Sutent	<input type="checkbox"/> Sylatron <input type="checkbox"/> Tafenlar <input type="checkbox"/> Tarceva <input type="checkbox"/> Tasigna <input type="checkbox"/> Temodar <input type="checkbox"/> Tykerb <input type="checkbox"/> Votrient <input type="checkbox"/> Xalkori <input type="checkbox"/> Xeloda <input type="checkbox"/> Xtandi <input type="checkbox"/> Zelboraf <input type="checkbox"/> Zykadia <input type="checkbox"/> Zytiga <input type="checkbox"/> Other	<b>STRENGTH:</b>  <b>SIG/DIRECTIONS/CYCLE:</b>  <b>REFILLS:</b>	<b>QUANTITY:</b>
---	--	---	------------------

Secondary Prescription- Drug Name: \_\_\_\_\_ Dose: \_\_\_\_\_

Sig/Directions/Cycle: \_\_\_\_\_ Quantity: \_\_\_\_\_ Refills: \_\_\_\_\_

**Clinical Information**

Primary Diagnosis:	ICD-9:	Weight:	Pounds	Height:	Inches
Secondary Diagnosis:	ICD-9:				

Allergies: \_\_\_\_\_ Failed Therapies: \_\_\_\_\_

Patient Medication List (or attach separately): \_\_\_\_\_

**Prescriber Information**


Prescriber First Name:	Prescriber Last Name:	Facility Name:
DEA:	State License #:	Office Contact E-mail:
Office Address:	NPI:	UPIN:
Office Phone:	City:	State:
Office Fax:	Office Contact Name:	
		Zip Code:

**SIGNATURE OF LICENSED PRESCRIBER IS REQUIRED TO VALIDATE PRESCRIPTIONS**

I authorize Advanced Care Scripts to initiate a Prior Authorization on my behalf.

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Prescriber must write "Brand Medically Necessary" in own handwriting to prevent substitution



**ACS** *Advanced Care Scripts*  
Omnicare Specialty Care Group


# Jadenu<sup>®</sup> (deferasirox) is now available through ACS Specialty Pharmacy.

**Jadenu<sup>®</sup>** is FDA-approved for the treatment of chronic iron overload due to blood transfusions in patients, and chronic iron overload in non-transfusion-dependent thalassemia syndromes (NTDT).

**By referring your patients to ACS, you and your patients can take full advantage of...**

- Access to oral and injectable therapies and including but not limited to Revlimid<sup>®</sup>, Pomalyst<sup>®</sup>, Tarceva<sup>®</sup>, Ibrance<sup>®</sup>, Sutent<sup>®</sup>, Nexavar<sup>®</sup>, Stivarga<sup>®</sup>, Gleevec<sup>®</sup>
- Blister packing for oral medications to improve medication adherence and compliance
- Patient counseling from expertly trained nurses and pharmacists
- Complete insurance investigation to determine the best financial option
  - ✓ Prior authorization initiation
  - ✓ Appeals assistance
  - ✓ Copayment assistance for patient

**Refer your patients in 3 easy steps!**



Questions? Please call your ACS Representative at 877-985-6337

To be removed from future faxes call 877-573-7105



ACS Advanced Care Scripts  
Oncology Specialty Care Group

# Oral Oncology Referral Form

Phone: 877-985-MEDS(6337)

Fax: 866-679-7131

### Patient Information OR Attach Face Sheet

First Name:	Middle Initial:	Last Name:	
Date of Birth:	Gender: <input type="checkbox"/> M <input type="checkbox"/> F	SSN:	
Street Address:	City:	State:	Zip Code:
Home Phone:	Work Phone:	Cell Phone:	

### Insurance Information OR Attach Insurance Information

Rx Card Insurance Name:	ID#:	BIN:	PCN:	Phone #:
Primary Insurance Name:	ID#:	GROUP#:		Phone #:
Secondary Insurance Name:	ID#:	GROUP:	Phone #:	

### Prescription Information

<b>POMALYST</b> Dosing: 1mg   2mg   3mg   4mg (circle one) Directions: _____ Qty: _____   Rest Period: _____ Auth number: _____ Date: _____ Confirmation: _____ Date: _____	<b>REVLIMID</b> Dosing: 2.5mg   5mg   10mg   15mg   20mg   25mg (circle one) Directions: _____ Qty: _____   Rest Period: _____ Auth number: _____ Date: _____ Confirmation: _____ Date: _____	<b>THALOMID</b> Dosing: 50mg   100mg   150mg   200mg (circle one) Directions: _____ Qty: _____   Rest Period: _____ Auth number: _____ Date: _____ Confirmation: _____ Date: _____	<b>Risk Category</b> <input type="checkbox"/> Adult Female, NOT of Reproductive Potential <input type="checkbox"/> Adult Female, Reproductive Potential <input type="checkbox"/> Adult Male <input type="checkbox"/> Male Child <input type="checkbox"/> Female Child, NOT of Reproductive Potential <input type="checkbox"/> Female Child, Reproductive Potential
--	--	---	--

### Drug List

<input type="checkbox"/> Afinitor <input type="checkbox"/> Bosulif <input type="checkbox"/> Emend <input type="checkbox"/> Erivedge <input type="checkbox"/> Farydak <input type="checkbox"/> Gleevec <input type="checkbox"/> Ibrance <input type="checkbox"/> Inlyta <input type="checkbox"/> Intron A <input type="checkbox"/> Jadenu <input type="checkbox"/> Mekinist <input type="checkbox"/> Nexavar <input type="checkbox"/> Promacta <input type="checkbox"/> Sprycel <input type="checkbox"/> Stivarga	<input type="checkbox"/> Sutent <input type="checkbox"/> Sylatron <input type="checkbox"/> Tafenlar <input type="checkbox"/> Tarceva <input type="checkbox"/> Tassigna <input type="checkbox"/> Temodar <input type="checkbox"/> Tykerb <input type="checkbox"/> Votrient <input type="checkbox"/> Xalkori <input type="checkbox"/> Xeloda <input type="checkbox"/> Xtandi <input type="checkbox"/> Zelboraf <input type="checkbox"/> Zykadia <input type="checkbox"/> Zytiga <input type="checkbox"/> Other	<b>STRENGTH:</b>  <b>SIG/DIRECTIONS/CYCLE:</b>  <b>REFILLS:</b>	<b>QUANTITY:</b>
--	--	---	------------------

Secondary Prescription- Drug Name: \_\_\_\_\_ Dose: \_\_\_\_\_  
 Directions/Cycle: \_\_\_\_\_ Quantity: \_\_\_\_\_ Refills: \_\_\_\_\_

### Clinical Information

Primary Diagnosis:	ICD-9:	Weight:	Pounds	Height:	Inches
Secondary Diagnosis:	ICD-9:				

Allergies: \_\_\_\_\_ Failed Therapies: \_\_\_\_\_

Patient Medication List (or attach separately):

### Prescriber Information

Prescriber First Name:	Prescriber Last Name:	Facility Name:
DEA:	State License #:	NPI: UPIN: Office Contact E-mail:
Office Address:	City:	State: Zip Code:
Office Phone:	Office Fax:	Office Contact Name:

### SIGNATURE OF LICENSED PRESCRIBER IS REQUIRED TO VALIDATE PRESCRIPTIONS

I authorize Advanced Care Scripts to initiate a Prior Authorization on my behalf.

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Prescriber must write "Brand Medically Necessary" in own handwriting to prevent substitution